Format

Send to

Choose Destination
Reprod Sci. 2016 Apr;23(4):429-38. doi: 10.1177/1933719115625842. Epub 2016 Jan 18.

In Vitro Activation: A Possible New Frontier for Treatment of Primary Ovarian Insufficiency.

Author information

1
Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
2
Department of Gynecology & Obstetrics-Reproductive Endocrinology and Infertility, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
3
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
4
Division of Reproductive Sciences and Women's Health Research, Department of Gynecology & Obstetrics-Reproductive Endocrinology, Johns Hopkins University School of Medicine, Baltimore, MD, USA jsegars2@jhmi.edu.

Abstract

In vitro activation (IVA) represents a new frontier in the treatment of women with primary ovarian insufficiency as well as patients with cancer desiring fertility preservation. Here, we review the biological basis of IVA and the recent translation of IVA to humans by targeting Hippo and Akt-signaling pathways. We then provide a new integrated viewpoint on IVA, highlighting basic science research on the aspects of follicular development and ovarian tissue transplantation which may potentially optimize future translational research on IVA. Specific topics discussed include cryopreservation techniques, additional IVA pathway targets, the roles of actin polymerization, paracrine and endocrine factors, and the role of mechanical signaling and associated tissue rigidity in controlling ovarian follicular activation. Further research and improved understanding is needed to optimize success of IVA.

KEYWORDS:

Akt stimulation; fertility preservation; in vitro activation; mechanical signaling; primary ovarian insufficiency

PMID:
26787101
DOI:
10.1177/1933719115625842
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center